Supporting Increased COVID-19 Testing Capacity

As a result of the COVID-19 pandemic, laboratories across the world are being asked to rapidly scale up their testing capacity. In response to this we have been configuring our ULTRA Laboratory Information System (LIS) to facilitate this increased testing demand. Click here to find out more  

Aalto Bio Reagents

COVID 19 Profile: In early 2020, Aalto Bio launched the first recombinant SARS-COVID 19 Nucleocapsid Protein for diagnostic test manufacturers, vaccine developers and researchers globally. The Nucleocapsid protein plays a fundamental role during vaccine assembly through its interactions with the viral genome and membrane protein M, and it also plays a vital part in enhancing… Read more »